P3H4 silencing suppresses tumor growth both in vitro and in vivo while simultaneously downregulating key glycolytic enzymes HK2 and LDHA, suggesting a potential metabolic vulnerability that could be therapeutically exploited. The gene discussed is P3H4; the disease is neoplasm.